Completed PHASE1 INTERVENTIONAL 2-arm NCT01421368

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users

Sponsor: CONRAD

Conditions HIV Prevention

Interventions Depo-medroxyprogesterone acetate (DMPA) Oral contraceptive: LNG 150 mcg and EE 30 mcg Tenofovir 1% vaginal gel

Updated 6 times since 2017 Last updated: Apr 9, 2015 Started: Mar 31, 2012 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Prevention, this trial is completed. The trial is conducted by CONRAD and has accumulated 6 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CONRAD

Data source: CONRAD

For direct contact, visit the study record on ClinicalTrials.gov .

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials